International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Journal
Blood
Journal Volume
140
Journal Issue
11
Pages
1200
Date Issued
2022-09-15
Author(s)
Arber, Daniel A
Orazi, Attilio
Hasserjian, Robert P
Borowitz, Michael J
Calvo, Katherine R
Kvasnicka, Hans-Michael
Wang, Sa A
Bagg, Adam
Barbui, Tiziano
Branford, Susan
Bueso-Ramos, Carlos E
Cortes, Jorge E
Dal Cin, Paola
DiNardo, Courtney D
Dombret, Hervé
Duncavage, Eric J
Ebert, Benjamin L
Estey, Elihu H
Facchetti, Fabio
Foucar, Kathryn
Gangat, Naseema
Gianelli, Umberto
Godley, Lucy A
Gökbuget, Nicola
Gotlib, Jason
Hellström-Lindberg, Eva
Hobbs, Gabriela S
Hoffman, Ronald
Jabbour, Elias J
Kiladjian, Jean-Jacques
Larson, Richard A
Le Beau, Michelle M
Loh, Mignon L-C
Löwenberg, Bob
Macintyre, Elizabeth
Malcovati, Luca
Mullighan, Charles G
Niemeyer, Charlotte
Odenike, Olatoyosi M
Ogawa, Seishi
Orfao, Alberto
Papaemmanuil, Elli
Passamonti, Francesco
Porkka, Kimmo
Pui, Ching-Hon
Radich, Jerald P
Reiter, Andreas
Rozman, Maria
Rudelius, Martina
Savona, Michael R
Schiffer, Charles A
Schmitt-Graeff, Annette
Shimamura, Akiko
Sierra, Jorge
Stock, Wendy A
Stone, Richard M
Tallman, Martin S
Thiele, Jürgen
Tzankov, Alexandar
Vannucchi, Alessandro M
Vyas, Paresh
Wei, Andrew H
Weinberg, Olga K
Wierzbowska, Agnieszka
Cazzola, Mario
Döhner, Hartmut
Tefferi, Ayalew
Abstract
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Publisher
Elsevier B.V.
Type
journal article